Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2011

View Archived Issues

Novartis offers overview of first quarter 2011

Cel-Sci receives approval to enroll patients in Canada in phase III Multikine trial

Merck & Co. discloses new NO-linked cicletanine derivatives

Novel xanthine oxidase inhibitors claimed by LG Life Sciences

Humanized monoclonal antibody XGFR-4 targets two signaling pathways in cancer

Antibody 12D7 shows therapeutic efficacy against cancer in combination with chemotherapy

Phase I and II data presented on ophthalmic agent SAR-1118

Bifunctional immune-mobilizing fusion proteins redirect immune system to destroy cancer cells

BAY-87-2243 suppresses tumor growth in vivo by targeting hypoxia-induced HIF1-alpha activation

Achaogen patents novel antibacterial aminoglycoside derivatives

Merck & Co. discloses new inhibitors of beta-secretase 1 and 2

Geron receives funding from CIRM for development of GRNOPC-1

IntraCellular Therapies reports novel radiolabeled PDE1 inhibitors

Karolinska Institutet presents novel series of selenium-containing antioxidants

Omeros' phosphodiesterase 7 inhibitors show preclinical efficacy in nicotine addiction

Algeta and Affibody to develop thorium-based tumor-targeting alpha pharmaceuticals

Revatio approved in E.U. for treatment of pulmonary arterial hypertension in children

Two-thirds of patients now enrolled in Serdaxin phase IIb trial

ImmunoCellular Therapeutics updates long-term data from phase I ICT-107 trial in glioblastoma

MMRF and Astellas Pharma Global Development to jointly develop OSI-906 in multiple myeloma

Advanced Life Sciences terminates staff and suspends operations

Oxford BioMedica and Pfizer expand licensing agreement for 5T4 antibody

Selexys Pharmaceuticals begins enrollment in phase I SelG1 study

AVI BioPharma begins phase I studies of AVI-6002 and AVI-6003

S*BIO regains rights to SB-1518 and SB-1578 from Onyx Pharmaceuticals

Santaris Pharma advances SPC-5001 to phase I for hypercholesterolemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...